News & Events
News & Events
Institut Pasteur Korea Introduced the Latest Research Strategy that Combines Deep Learning and New Drug Development at Bio Korea 2021
2021-06-24
Institut Pasteur Korea Introduced the Latest Research Strategy that Combines Deep Learning and New Drug Development at Bio Korea 2021
Institut Pasteur Korea (IPK) held a Satellite Session under the theme of < Deep-learning Enhanced Therapeutics Discovery> at the 2021 Bio Korea held in COEX (Seoul) and online from June 9 to 11.
IPK CEO Dr. Youngmee Jee and CSO Dr. Spencer Shorte, the co-chairs, shared and discussed the latest research trends along with domestic and foreign experts who are leading the drug development leveraging Artificial Intelligence (AI), including Dr. Sang Ok Song, the Chief Operating Officer of Standigm Inc., Dr. Wankyu Kim, the CEO of KaiPharm Co., Ltd., Dr. Niranj Chandrasekaran of Broad Institute of Harvard and MIT, Dr. Inhee Choi, the head of Medicinal Chemistry of IPK, and Dr. Spencer Shorte. The speakers presented on the status of research and collaboration for the development of therapeutics for infectious diseases and non-communicable diseases (such as cancer), immune regulation, and chronic inflammatory diseases. In particular, Dr. Shorte, the leader of the “Pasteur Joint International Research Unit for development of next-generation technology for infectious disease therapeutic discovery” built in cooperation with Institut Pasteur Korea and Institut Pasteur (Paris), introduced the latest strategy for utilizing deep learning to analyze the biological images produced through phenotypic screening, IPK’s core drug discovery technology.
.png)
(Picture on the left, clockwise from the top left) CEO Dr. Youngmee Jee, Prof. Wankyu Kim, Dr. Niranj Chandrasekaran, Dr. Spencer Shorte, Dr. Inhee Choi, Dr. Sangok Song
CEO Dr. Jee spoke, "With global efforts to respond to COVID-19, 10% of the world's population has already achieved remarkable results of getting vaccinated, but the development of therapeutics remains yet unresolved requiring further research and investment.” She continued, “Today’s discussions were helpful to better understand the new paradigm of AI- and deep learning-based drug development, which can be applied effectively to facilitate the development of treatment methods to strengthen infectious diseases preparedness and response.”
To make AI and deep learning a driving force to advance the pharmaceutical field, the speakers voiced the need, besides technology and data, for active communication and collaboration between related institutions and researchers and for support such as funding and policies that facilitate the proactive and effective utilization of AI and deep learning.
In particular, Dr. Shorte mentioned, “Korea, which is rich with talent in fields such as computer/data science and biology, will be able to play a pivotal role in the global network based on its practical science expertise.” He revealed, “We can refer to the examples of EMBL-EBI, Kingston, and Cambridge in Europe or the United States, which are currently the center of open science data, and we need to consider strategies and policies for sharing, utilizing, and maintaining vast amounts of data that are continuously generated.”
Please refer to the attached abstract for more details.